Vanguard Capital Management
ELVN icon

Vanguard Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Vanguard Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130M Buy
2,569,002
+400,840
+18% +$17M ﹤0.01% 1412
2026
Q1 		$85M Buy
+2,168,162
New +$60.1M ﹤0.01% 1567

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Capital Management's ELVN Position: Q2 2026 in Review

Vanguard Capital Management increased its Enliven Therapeutics (ELVN) stake by 18% in Q2 2026, buying an estimated $17M and bringing the position to 2,569,002 shares worth $130M. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Vanguard Capital Management first reported a position in ELVN in Q1 2026 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Vanguard Capital Management held 2,569,002 shares of Enliven Therapeutics worth $130M as of Q2 2026.
  • Vanguard Capital Management bought 400,840 Enliven Therapeutics shares in Q2 2026, an estimated $17M.
  • Enliven Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1412 holding.
  • Vanguard Capital Management first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.